Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; we may never receive marketing approval for carfilzomib or regorafenib; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; if approved, we or Bayer, as the case may be, may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib or regorafenib; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, regorafenib or carfilzomib; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, as updated by Onyx's subsequent Quarterly Reports on Form 10-Q, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables)ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2011201020112010Revenue: Revenue from collaboration agreement

$  75,041$63,696$ 
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 IGI Laboratories, ... based specialty generic pharmaceutical company, today announced ... its Board of Directors.  Mr. Finio has accepted a ... under the terms of his acceptance of his new ... his role as Director for IGI Laboratories, Inc.  The ...
(Date:7/24/2014)... Many new dentists who are opening their own ... their practice will be a success. DentalDisposables.net is here to ... the most can make all the difference. Dentistry is a ... that purchasing discount dental supplies can make the ... successful dentists across the United States ...
(Date:7/24/2014)... 24, 2014  Perrigo Company (NYSE: PRGO ... AB therapeutic equivalent rating from the U.S. Food and ... Application (NDA) for testosterone gel 1.0%. FDA concluded that ... 1% and can be substituted with the full expectation ... safety profile as AndroGel 1% when used under the ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Dental Supplies Online is Key to Dental Success...Really! 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... The U.S. Food and Drug Administration today approved the ... to treat certain infections in people ages 18 and ... Levofloxacin is used to treat mild, moderate, or ... and prostate caused by specific germs. It also is ...
... The Consumer Healthcare Products Association (CHPA) released the ... Perry signing into law legislation that implements a ... common cold and allergy medicines containing pseudoephedrine (PSE), ... "We applaud the work of Texas ...
Cached Medicine Technology:FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections 2
(Date:7/25/2014)... Phoenix, AZ (PRWEB) July 25, 2014 ... firm offering discount attorney’s fees with regard to ... Hastings provide a wide range of legal services ... of the negligence of another individual or corporation. Free ... of determining the validity of a potential personal ...
(Date:7/25/2014)... for lymphoma may lower men,s fertility, new research indicates. ... cancers of the body,s white blood cells, often affect ... For men, treatment for these cancers can harm or ... within two years of treatment, the researchers cautioned that ... significant side effect before treatment begins. "While many ...
(Date:7/25/2014)... 2014 Parkulture is proud ... and parkour instructor, Jared “JJ” Woods, will be competing ... American Ninja Warrior. The show will premiere on local ... will rerun on the new Esquire Network on Tuesday, ... resident, has been balancing careers as a professional stuntman ...
(Date:7/25/2014)... The Rottenstein Law Group LLP, ... 25 years of experience advocating for plaintiffs with ... announces the launch of its new website, ... believe they have been harmed by the prescription ... information about the severe adverse side effects allegedly ...
(Date:7/25/2014)... Twins, genes may play a greater role in language ... Researchers found more evidence that language traits, ... largely inherited. The study involving 473 sets of ... of language performance for twins than single-born children) was ... finding disputes hypotheses that attribute delays in early language ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Genes May Be Key to Language Delay in Kids 2
... is very rare, affecting approximately one in every 100,000 ... i.e. they are born with empty eye sockets. This ... in the normal way in the first 28 days ... fitted with prosthetic eyes to allow normal facial// development. ...
... which occurs when the heart becomes so enlarged that it ... affects 35 in every 100,000 people. Researchers in the United ... journal Science that a defect in the gene phospholamban may ... the flow of calcium through the heart, enabling it to ...
... using a new imaging technique based on Magnetic Resonance ... now, MRI was used to show how Alzheimer's disease ... for memory and learning. And post-mortem studies revealed how ... the first time a three-dimensional time lapse video of ...
... by scientists at the Johns Hopkins School of Public Health ... have called for urgent research into the impact of soya ... chemical in soya can damage the male reproductive organs. Though ... effect on humans, its effects on rats were so severe ...
... published in the February issue of the British Medical Journal ... more at risk of heart disease later in life than ... live infant in Scotland during the years 1981-85, were identified ... miscarriage or repeated miscarriages. Then, during 1981 to 1999, the ...
... blood has been believed to be the most ... heart disease is associated with increased levels of ... LDL(Low-Density Lipoprotein)or 'bad' cholesterol and HDL(High-Density Lipoprotein) or ... researchers in Canada and Sweden are now putting ...
Cached Medicine News:Health News:Miscarriage during pregnancy and heart disease linked 2
... designed for low to medium throughput reading of ... from one to three racks and reads in ... are exported via text files and a list ... integration with other programs. System includes a USB ...
... steel work surface. Pneumatic ... to protect operator, as ... equipment from the workstation. ... for multiple vibration-free work ...
... top with powder-coated steel legs. ... Available in hundreds of sizes ... drawers, light fixtures and ionizing ... in custom building to meet ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
Medicine Products: